Key clinical point: Nonbiologic systemic therapies still have a place for treatment of psoriasis.
Major finding: Oral apremilast is recommended for moderate to severe psoriasis
Study details: Guidelines developed by a committee of the American Academy of Dermatology and National Psoriasis Foundation.
Disclosures: Dr. Menter and Dr. Elmets disclosed financial relationships with numerous pharmaceutical companies. Other authors/work group members also had disclosures related to pharmaceutical manufacturers, and several had no disclosures.
Menter A et al. J Am Acad Derm. 2020 Feb 28. doi: 10.1016/j.jaad.2020.02.044.